MARKET

AZRX

AZRX

AzurRx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7520
-0.0260
-3.34%
Closed 18:56 05/11 EDT
OPEN
0.7270
PREV CLOSE
0.7780
HIGH
0.7794
LOW
0.7100
VOLUME
1.03M
TURNOVER
--
52 WEEK HIGH
2.630
52 WEEK LOW
0.6501
MARKET CAP
55.98M
P/E (TTM)
-0.5222
1D
5D
1M
3M
1Y
5Y
AzurRx BioPharma to Present at the Emerging Growth Conference (May 12)
DELRAY BEACH, Fla., May 11, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI...
GlobeNewswire · 19h ago
AzurRx BioPharma to Present at Investor Summit Group’s Q2 Virtual Investor Summit (May 17)
DELRAY BEACH, Fla., May 11, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ: AZRX), (“AzurRx” or the “Company”), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI...
GlobeNewswire · 20h ago
AzurRx BioPharma Announces Participation in the Q2 Virtual Investor Summit
Delray Beach, Florida--(Newsfile Corp. - May 11, 2021) - AzurRx BioPharma (NASDAQ: AZRX) today announced that James Sapirstein, Chairman, President, and CEO will be attending the Q2 Virtual Investor Summit. Event Q2 Investor Summit Date May 17-18th, 2021 P...
Newsfile · 21h ago
CEO Presenting on the Emerging Growth Conference on May 12. Register here
GlobeNewswire · 1d ago
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
Zacks.com · 05/03 14:48
Global Exocrine Pancreatic Insufficiency Market Trend 2021 - 2025 with Top-Countries Data And Covid-19 Analysis, by Industry Trends, Size, Share, Company Overview, Growth, Development and Forecast
May 03, 2021 (The Expresswire) -- Global “Exocrine Pancreatic Insufficiency Market” Report 20212025 covers the worldwide and regional market with an in-depth...
The Express Wire · 05/03 05:41
Merrion Investment Management Co, LLC Buys Williams Inc, DISH Network Corp, Facebook Inc, Sells ...
GuruFocus News · 04/29 15:38
41 Stocks Moving In Wednesday's Mid-Day Session
Gainers Aurora Mobile Limited (NASDAQ: JG) shares climbed 21.3% to $4.27 after Oppenheimer initiated coverage on the stock with an Outperform rating and a price target of $6 per share.
Benzinga · 04/28 16:06
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AZRX. Analyze the recent business situations of AzurRx through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AZRX stock price target is 3.500 with a high estimate of 5.00 and a low estimate of 2.500.
EPS
Institutional Holdings
Institutions: 36
Institutional Holdings: 4.19M
% Owned: 5.63%
Shares Outstanding: 74.44M
TypeInstitutionsShares
Increased
6
241.07K
New
4
224.24K
Decreased
2
56.21K
Sold Out
3
31.28K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.55%
Pharmaceuticals & Medical Research
-0.29%
Key Executives
Chairman/Independent Director
Edward Borkowski
President/Chief Executive Officer/Director
James Sapirstein
Chief Financial Officer
Daniel Schneiderman
Other
James Pennington
Independent Director
Charles Casamento
Independent Director
Gregory Oakes
Independent Director
Alastair Riddell
Independent Director
Vern Schramm
No Data
About AZRX
AzurRx BioPharma, Inc. is a clinical development-stage biopharmaceutical company. The Company is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal (GI) disorders. The Company's product pipeline consists of two therapeutic proteins, such as MS1819 and AZX1101. MS1819 is an acid-resistant secreted lipase produced by Yarrowia lipolytica, known as LIP2, that the Company is developing through recombinant deoxyribonucleic acid (DNA) technology for the treatment of exocrine pancreatic insufficiency (EPI), associated with chronic pancreatitis (CP) and cystic fibrosis (CF). AZX1101 is a recombinant-lactamase combination of bacterial origin under development for the prevention of hospital-acquired infections by resistant bacterial strains induced by parenteral administration of b-lactam antibiotics (known as nosocomial infections), as well as the prevention of antibiotic-associated diarrhea (AAD).

Webull offers kinds of AzurRx BioPharma Inc stock information, including NASDAQ:AZRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AZRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AZRX stock methods without spending real money on the virtual paper trading platform.